» Articles » PMID: 18694952

A Nonsense Mutation in the ERG6 Gene Leads to Reduced Susceptibility to Polyenes in a Clinical Isolate of Candida Glabrata

Overview
Specialty Pharmacology
Date 2008 Aug 13
PMID 18694952
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Unlike the molecular mechanisms that lead to azole drug resistance, the molecular mechanisms that lead to polyene resistance are poorly documented, especially in pathogenic yeasts. We investigated the molecular mechanisms responsible for the reduced susceptibility to polyenes of a clinical isolate of Candida glabrata. Sterol content was analyzed by gas-phase chromatography, and we determined the sequences and levels of expression of several genes involved in ergosterol biosynthesis. We also investigated the effects of the mutation harbored by this isolate on the morphology and ultrastructure of the cell, cell viability, and vitality and susceptibility to cell wall-perturbing agents. The isolate had a lower ergosterol content in its membranes than the wild type, and the lower ergosterol content was found to be associated with a nonsense mutation in the ERG6 gene and induction of the ergosterol biosynthesis pathway. Modifications of the cell wall were also seen, accompanied by increased susceptibility to cell wall-perturbing agents. Finally, this mutation, which resulted in a marked fitness cost, was associated with a higher rate of cell mortality. Wild-type properties were restored by complementation of the isolate with a centromeric plasmid containing a wild-type copy of the ERG6 gene. In conclusion, we have identified the molecular event responsible for decreased susceptibility to polyenes in a clinical isolate of C. glabrata. The nonsense mutation detected in the ERG6 gene of this isolate led to a decrease in ergosterol content. This isolate may constitute a useful tool for analysis of the relevance of protein trafficking in the phenomena of azole resistance and pseudohyphal growth.

Citing Articles

Acquired amphotericin B resistance leads to fitness trade-offs that can be mitigated by compensatory evolution in Candida auris.

Carolus H, Sofras D, Boccarella G, Sephton-Clark P, Biriukov V, Cauldron N Nat Microbiol. 2024; 9(12):3304-3320.

PMID: 39567662 DOI: 10.1038/s41564-024-01854-z.


Fungal Infections, Treatment and Antifungal Resistance: The Sub-Saharan African Context.

Boakye-Yiadom E, Odoom A, Osman A, Ntim O, Kotey F, Ocansey B Ther Adv Infect Dis. 2024; 11:20499361241297525.

PMID: 39544852 PMC: 11562003. DOI: 10.1177/20499361241297525.


Impact of ERG6 Gene Deletion on Membrane Composition and Properties in the Pathogenic Yeast Candida glabrata.

Jacko J, Morvova Jr M, Hervay N, Elias D, Gbelska Y, Waczulikova I Cell Biochem Biophys. 2024; .

PMID: 39477913 DOI: 10.1007/s12013-024-01599-w.


Insights into the role of sterol metabolism in antifungal drug resistance: a mini-review.

Tanwar S, Kalra S, Bari V Front Microbiol. 2024; 15:1409085.

PMID: 39464401 PMC: 11502366. DOI: 10.3389/fmicb.2024.1409085.


Resistance Mechanisms of Plant Pathogenic Fungi to Fungicide, Environmental Impacts of Fungicides, and Sustainable Solutions.

Islam T, Danishuddin , Tamanna N, Matin M, Barai H, Haque M Plants (Basel). 2024; 13(19).

PMID: 39409607 PMC: 11478979. DOI: 10.3390/plants13192737.


References
1.
Defontaine A, Bouchara J, Declerk P, Planchenault C, Chabasse D, Hallet J . In-vitro resistance to azoles associated with mitochondrial DNA deficiency in Candida glabrata. J Med Microbiol. 1999; 48(7):663-670. DOI: 10.1099/00222615-48-7-663. View

2.
Ellis D . Amphotericin B: spectrum and resistance. J Antimicrob Chemother. 2002; 49 Suppl 1:7-10. DOI: 10.1093/jac/49.suppl_1.7. View

3.
Niimi M, Niimi K, Takano Y, Holmes A, Fischer F, Uehara Y . Regulated overexpression of CDR1 in Candida albicans confers multidrug resistance. J Antimicrob Chemother. 2004; 54(6):999-1006. DOI: 10.1093/jac/dkh456. View

4.
Richardson M . Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother. 2005; 56 Suppl 1:i5-i11. DOI: 10.1093/jac/dki218. View

5.
Fidel Jr P, Vazquez J, Sobel J . Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev. 1999; 12(1):80-96. PMC: 88907. DOI: 10.1128/CMR.12.1.80. View